Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That ask is getting stacked now! Better come out with some news or back to no bid and no volume.
Let's smack that ask today folks! I want my 1s to look even better.
What's tomorrow?
Bid just got dumped. 3 x 4 up.
On watch.
Chipping away @ 7s. 9885913 x 21902843
7s falling!
Boom! 6s getting hit hard. $ZNTR
6s real thin. 5646000 x 24350000
Shaking the tree. 5 x 6 will be back up soon.
5 x 6 up. $ZNTR
Great close yesterday!
Boom! Over 100m support @ 4 now. $ZNTR
Boom! 4 x 5 up again. Power hour should be interesting. $ZNTR
4s getting hit hard now. 17m left.
Boom! Nice 12 milly smack @ 4! $ZNTR churning again.
Nice support! 164156400 x 47895000. 4s about to start falling again. $ZNTR
Bid bigger then the ask now. 56331400 x 54535000
Support building again. 19300000 x 44136666
4s printing again.
Boom! 4 x 5 up with support! $ZNTR
4s getting hit hard. 20m left. $ZNTR
Nice 3 milly smack @ 4!
Glad we got you out of the way quickly. Sorry about your luck.
Volume alert. 31m traded so far. $ZNTR
35062064 x 27919600. 4s pretty thin.
Boom! 3 x 4 up with support. $ZNTR churning.
Nice 10 milly smack @ 3! Bid building. 56716100 x 29468600. $ZNTR
Nice 3 milly smack @ 3 to start the day. $ZNTR
.07s dumping.
Grabbed some .09s
Timber....waiting on a nickel.
Some more action today. Keep it coming. $ZNTR
Still a few more 2s left but we're on our 8th straight day with volume.
Not yet.
Second Quarter 2017 Common Stock Dividends
Month Dividend Record Date Payment Date
April 2017 $0.05 April 17 April 27
May 2017 $0.05 May 15 May 30
June 2017 $0.05 June 15 June 29
News out. MSTX announced today it has set a date for a special meeting of its stockholders to vote on matters related to the proposed merger with Savara Inc. (Savara), a privately-held, clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases.
The special meeting will be held at 9:00 a.m., local time, on April 21, 2017 at 3611 Valley Centre Drive, Suite 500, San Diego, California 92130. Mast's stockholders of record as of the close of business on March 13, 2017 are entitled to receive notice of, and to vote at, the special meeting.
The merger has been unanimously approved by the boards of directors of both companies and the board of directors of Mast unanimously recommends that its stockholders vote "FOR" the special meeting proposals described in the proxy statement/prospectus/information statement declared effective by the Securities and Exchange Commission on March 15, 2017, a copy of which will be provided to Mast stockholders of record as of March 13, 2017. The proposed merger is expected to close promptly after the Mast special meeting scheduled for April 21, 2017, subject to the approval of the stockholders of each company and the satisfaction or waiver of the other closing conditions in the merger agreement between the companies.
The combined company would advance a pipeline of novel inhalation therapies for the treatment of diseases with significant unmet medical needs, featuring three product candidates, each in advanced stages of clinical development:
-- AeroVanc, an inhaled dry-powder vancomycin to treat chronic methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection in cystic fibrosis (CF) in preparation for a pivotal Phase 3 study;
-- Molgradex, an inhaled nebulized GM-CSF to treat pulmonary alveolar proteinosis (PAP) currently in Phase 2/3 development; and
-- AIR001, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction (HFpEF) currently in Phase 2 development.
Select Anticipated Upcoming Development Milestones
-- Closing of proposed merger in Q2/2017.
-- Initiate a pivotal Phase 3 study of AeroVanc in Q3/2017.
-- Complete negotiations with the U.S. Food and Drug Administration (FDA) on the requirements for a pivotal clinical study of Molgradex in the U.S. in Q3/2017.
-- Announce strategy related to Molgradex program expansion for the treatment of a rare lung infection in 2017.
-- Announce top-line results from Phase 2/3 study of Molgradex, expected to be registration-enabling for the treatment of PAP in Europe and Japan, in Q1/2018.
-- Announce results from ongoing Phase 2 study of AIR001 for the treatment of HFpEF being conducted by the Heart Failure Clinical Research Network in Q1/2018.
2s building up again. 30180000 x 50566945
New 52 week low.
"Heading towards the 8 cent range" ETA?
11s print. Come to papa.